Results 261 to 270 of about 3,580,419 (303)
Some of the next articles are maybe not open access.
Clinical Orthopaedics and Related Research, 2003
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +2 more sources
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +2 more sources
Current Opinion in Oncology, 1996
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
Current Opinion in ONCOLOGY, 1993
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources
CTCs in Metastatic Breast Cancer
2012Circulating tumor cells (CTCs), enumerated by the Food and Drugs Administration-cleared CellSearch(®) system, are an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients.
Giordano A., Cristofanilli M.
openaire +3 more sources
Chemotherapy for Metastatic Breast Cancer
Hematology/Oncology Clinics of North America, 2007Cytotoxic chemotherapy is a mainstay of treatment for advanced breast cancer. Treatment of metastatic (also called stage IV, advanced, or recurrent) breast cancer is not considered curative. Rather, the goals of treatment with chemotherapy are to prolong survival, alleviate or prevent tumor-related symptoms or complications, and improve quality of life.
Erica L, Mayer, Harold J, Burstein
openaire +2 more sources
Ovarian cancer metastatic to the breast
Gynecologic Oncology, 2006Metastatic ovarian cancer to the breast should be considered in the differential diagnosis for gynecologic cancer patients with a breast tumor. Despite early detection and treatment, the long-term prognosis for these patients is poor.We present three ovarian cancer patients who developed metastatic ovarian cancer to the breast.
John P, Micha +4 more
openaire +2 more sources
Chemotherapy for metastatic breast cancer
Current Opinion in Obstetrics and Gynecology, 2004This review is intended to summarize the most up-to-date information in the field of chemotherapy for advanced breast cancer.During the past year, the literature on chemotherapy for metastatic breast cancer has focused on three main areas of interest: the development of new cytotoxic agents with most studies addressing the taxane-pretreated population;
Laura, Biganzoli +3 more
openaire +2 more sources
Living with Metastatic Breast Cancer
2015Although prevalence estimates are imprecise, growing numbers of women in the United States are living longer with metastatic breast cancer, attributable at least in part to the availability of effective targeted therapies. Women living with metastatic disease are understudied, however, and substantial heterogeneity exists in both the clinical ...
Patricia A, Ganz, Annette L, Stanton
openaire +2 more sources
Management of metastatic breast cancer
World Journal of Surgery, 1994AbstractSystemic treatment almost certainly prolongs the median survival of women with metastatic breast cancer, and it may prolong the survival of a small number of patients substantially. Even with conventional therapy, 10% or more patients may live into the second decade after recurrence.
K, Wong, I C, Henderson
openaire +2 more sources
Vulvar cancer metastatic to the breast
Gynecologic Oncology, 2006Vulvar cancer rarely sends metastases to distant sites.A 49-year-old female presented with a vulvar mass. The histologic examination revealed an infiltrating lesion with free surgical margins and no evidence of lymph node involvement. Four months following surgery, due to a bloody breast discharge and a palpable breast lump an excisional biopsy was ...
D, Vicus +4 more
openaire +2 more sources